Expedited Review of New Drugs or New Indications for Drugs in the Six Classes of Clinical Concern

Please see the attached memo from Cynthia Tudor, Ph.D., Director, Medicare Drug Benefit Group, regarding the expedited review of new drugs or new indications for drugs in the six classes of clinical concern.

Thank you.